In the phase 3, 12-month Trial Assessing Injectable Interferon versus FTY720 Oral in Relapsing–Remitting Multiple Sclerosis (TRANSFORMS), fingolimod, the first oral therapy approved for the treatment of relapsing MS, demonstrated a significant reduction in annualized relapse rate (ARR) compared with intramuscular IFN beta-1a (ARR was 0.16 in the fingolimod group compared with 0.33 in patients treated with IFN; p<0.001) [23]. This evidence concerns the gene IFNA1 and multiple sclerosis.